Searchable abstracts of presentations at key conferences in endocrinology

ea0025p24 | Bone | SFEBES2011

Management of primary hyperparathyroidism

Palalau Anna Irina , Raskauskiene Diana

Primary hyperparathyroidism (PHPT) is a common reason for referral to the endocrinology team. We aimed to estimate the prevalence of associated vitamin D deficiency and osteoporosis, to evaluate the usefulness of imaging studies in identifying a parathyroid adenoma prior to surgery and to assess response to surgical treatment in the setting of a District General Hospital.We searched our outpatient clinic letters and identified 64 patients diagnosed with ...

ea0011p616 | Neuroendocrinology and behaviour | ECE2006

Rate of change in size of macroprolactinomas with dopamine agonist therapy – is there any relationship to fall in prolactin concentrations?

Miller CL , Palalau A , Toogood AA , Gittoes NJL

The most effective means of treating macroprolactinomas, including those associated with significant visual loss at presentation, is with dopamine agonist (DA) therapy. Improvement in visual function often occurs within days of commencing DA therapy, and usually precedes significant reductions in prolactin (PRL) concentrations and may predate significant evidence of tumour volume reduction by months or years. The temporal association between PRL concentration reductions and tu...

ea0011p507 | Endocrine tumours and neoplasia | ECE2006

Contemporary management of macroprolactinomas

Palalau AI , Miller C , Gittoes NJ , Toogood AA

Contemporary management of macroprolactinomas relies heavily on the use of dopamine agonist (DA) therapy. However, historically a proportion of patients may have undergone surgery and/or pituitary radiotherapy. We aimed to determine the long-term outcome in terms of tumour control and prolactin normalisation in a large cohort of patients with macroprolactinoma who received various treatment modalities. 80 patients (54 male) with macroprolactinoma (tumour diameter >10 mm, p...